Merck Serono presents new MS data at AAN meeting

Merck Serono has presented new clinical data from its multiple sclerosis (MS) portfolio at the annual meeting of the American Academy of Neurology (AAN).

The company has been attending the industry conference in New Orleans this week in order to showcase new data on its established therapy option Rebif, as well as the investigational product ONO-4641.

Rebif data presented at the event showed the benefits offered by the treatment across a range of patient groups and specifications, including indications for which the company is yet to receive approval in the US.

Meanwhile, results from phase II studies also showed the potential efficacy of ONO-4641, which is being developed in collaboration with Ono Pharmaceuticals.

Dr Annalisa Jenkins, head of global drug development and medical at Merck Serono, said: "We are committed to advancing multiple sclerosis care, research and outcomes in order to provide treatments for people living with this devastating disease."

Last month, the company announced a collaboration with Threshold Pharmaceuticals, which will focus on the development of a new oncology treatment.